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DDiscussion
Dr Ross M. Ungerleider, MD (Cleveland, Ohio). The topic is
timely. It is controversial and important as we try to find ways to
extend the time before valve replacement in our young population.
I want to ask you some questions that can help us understand
when to use your techniques in lieu of more conventional treat-
ments. I have spent a lot of time trying to understand the numbers
in your article and the numbers you presented today. Your study, as
you mentioned, is retrospective. It lacks comparison with a control
group treated by more conventional means, and as youmentioned it
also is subject to selection bias. You mentioned that you only
selected the patients with more complex problems. The patients
with more typical problems were treated by more usual techniques.
So for which patient is ACEVwith or without tricuspidization more
desirable than simple balloon valvotomy? You had 50 patients with
BAV and 40 patients with congenital AS, most aged more than 2
years. These patients would likely be treated in most centers by bal-
loon valvotomy, but only 20% of your patients in these groups have
balloon valvotomy before ACEV. Can you give us insight into why
you selected your patients for ACEV versus valvotomy and do you
have any outcome data comparing themwith the patient groups that
you apparently selected for simple valvotomy? I am having trouble
understanding why an ACEV was necessary for these patients with
predominant AS.
The literature would tend to support that freedom from AVR is
excellent after balloon valvotomy for older patients similar to the
ones in your series. For the patients who had AI, you had 41
patients with AS/AI and 8 patients with what you called other valve
pathology, yet you state that 49 patients received ACEV for severe
AI and an additional 9 patients received ACEV for moderate AI.
Does that number include a crossover from the bicuspid or congen-
ital AS group? As I looked at your numbers, it appeared that 44% of
patients in your series had ACEV for AI, leaving 56% having
ACEV for predominantly AS. This is potentially useful data for
you to have because you can create some comparison groups. Do
you have data to show if there is a difference in the freedom
from AVR in one group versus another? In particular, it might be
useful if you could compare for us the results of ACEV for AI
versus ACEV for AS and then ACEV plus tricuspidization for
AS, which is a uniquely different treatment group.
I am particularly concerned that you have not really explained to
us the benefits of tricuspidization compared with simple valvotomy
for BAV, and it would be helpful if you could determine whether
the ACEV group fared better than the balloon valvotomy groupThe Journal of Thoracic and Cafor AS in terms of putting off the time until AVR in these simi-
lar-aged patients. I am puzzled about the role for ACEV. Without
randomization and comparison with controls (simple valvotomy),
it is difficult to understand whether there is any useful role for
ACEV as you have described it.
You mentioned that you changed to a less intense fixation of
pericardium to improve the results of your ACEV, yet you don’t
give us any indication of what the problems were with the more
intensely treated pericardium. I wonder if you have any experience
with polytetrafluoroethylene (Gore-Tex; WL Gore & Associates,
Newark, DE) membrane for aortic cusp valve extension. I have
had good results so far with that.
Finally, going forward with your experience, as you help us
understand when to select patients for ACEV, what would you rec-
ommend for a 6-year-old with BAV, a normal annulus, a mean gra-
dient of 60 mm Hg, no AI, and an increase in LV wall mass?
Dr Polimenakos. Starting with your first comment and ques-
tion, I would say that most of these patients who present actually
require complex repair. We excluded patients who had simple val-
votomies or valvuloplasties that did not require extensive recon-
struction in the form of ACEV. That includes a group of patients
who had original valvotomy or valvuloplasty, and they did not
reach that level of AI to justify ACEV. As I mentioned to you be-
fore, I think if we have a gradually increased LVED after balloon
valvuloplasty, in that subset of patients you mentioned, and in
addition to that there is a regurgitant jet to aortic annulus diameter
greater than 35% to 40%, we recommend ACEV for these patients.
I totally agree with you that the specific subset of patients with
congenital AS is a group with early failure and recurrent AS.
That is why according to the original experience, over the last
few years we have been very selective offering ACEV to this sub-
category of patients. We encourage these patients to have some
form of valve replacement (probably in the form of Ross), particu-
larly the smaller patients.
In terms of your second question, there are some crossovers as
you mentioned. That is because a lot of the patients with BAV
had either predominantly AI when they presented to us, as a referral
center, or combined AI/AS. Some of them had even balloon valvu-
loplasty before that. That is why, as I mentioned, it is not a simple
repair that we just reinforce the commissure or repair a torn cusp.
Most of these patients have moderate to severe AI or a combination
AI and AS. Again, patients with congenitally related AS were one
of the subgroups originally attempted to be repaired, but currently
we do not recommend this technique, especially if the aortic valve
annulus has a z-value of1.5 or less.
In terms of your final question, this is actually an ongoing study.
We are going to look into the different surgical eras because, as I
mentioned to you before, we moved from glutaraldehyde-treated
autologous pericardium with 10 minutes of glutaraldehyde treat-
ment gradually down to, currently, 3 minutes.
Dr Ungerleider. But you switched because you were seeing
more progressive AI?
Dr Polimenakos. We were seeing more neocusp calcification
and fibrosis with predominantly AI. Some of these patients pre-
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